{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:43:43Z","timestamp":1787021023678,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Bonn"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol. Res. Pract."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Fabry disease (FD) is an X-linked lysosomal storage disorder caused by mutations in the \u03b1-galactosidase A (\n                      <jats:italic>GLA<\/jats:italic>\n                      ) gene, leading to an increased risk for white matter lesion (WML), stroke and cerebral microbleeds. Utilizing MRI data from the prospective observational FAMOUS study we assessed MRI characteristics of FD and treatment effects of migalastat.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>19 patients with pathogenic (PV) and 14 patients with likely benign genetic variants (LBV: p.A143T, p.D313Y, and p.S126G) underwent MRI at baseline and 24 month-follow up under migalastat treatment. WML load, using Fazekas and Scheltens scores, basilar artery diameter (BAD), and the occurrence of strokes and cerebral microbleeds were assessed. Patients were compared by variant type (PV\/LBV) and presence of arterial hypertension.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>WML load was low to moderate and remained stable. Four PV patients showed progress by visual examination. WML load was similar between PV and LBV groups. Patients with arterial hypertension had a higher Scheltens score. PV patients had higher BAD. No patient showed cerebral microbleeds. One PV patient with coincident multiple sclerosis demonstrated a positive central vein sign.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our data suggest that microangiopathic lesion load remains relatively stable under migalastat. Antihypertensive therapy may be important to reduce WML in FD. Further studies are needed to assess the cerebral effect of migalastat therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42466-025-00440-w","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:23:55Z","timestamp":1765884235000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of migalastat on cerebral outcomes in fabry disease \u2013 results from the prospective observational FAMOUS trial"],"prefix":"10.1186","volume":"7","author":[{"given":"Momoko","family":"Choudhury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Lenders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Laufer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Masthoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Canaan-K\u00fchl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Kurschat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Muschol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia B.","family":"Hennermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Cybulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Kaufeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3862-5738","authenticated-orcid":false,"given":"Antje","family":"Bischof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"440_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain, D. P. (2010). Fabry disease. Orphanet Journal of Rare Diseases, 5, 30.","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"5","key":"440_CR2","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0035-3787(06)75051-2","volume":"162","author":"P Clavelou","year":"2006","unstructured":"Clavelou, P., Besson, G., Elziere, C., Ferrier, A., Pinard, J. M., Hermier, M., Artigou, J. Y., & Germain, D. P. (2006). Manifestations neurologiques de La maladie de Fabry [Neurological aspects of fabry\u2019s disease]. Revue Neurologique, 162(5), 569\u2013580.","journal-title":"Revue Neurologique"},{"issue":"3","key":"440_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ymgme.2018.08.014","volume":"125","author":"S K\u00f6rver","year":"2018","unstructured":"K\u00f6rver, S., Vergouwe, M., Hollak, C. E. M., van Schaik, I. N., & Langeveld, M. (2018). Development and clinical consequences of white matter lesions in Fabry disease: A systematic review. Molecular Genetics and Metabolism, 125(3), 205\u2013216.","journal-title":"Molecular Genetics and Metabolism"},{"issue":"33","key":"440_CR4","doi-asserted-by":"publisher","first-page":"6014","DOI":"10.2174\/13816128113199990387","volume":"19","author":"A Tuttolomondo","year":"2013","unstructured":"Tuttolomondo, A., Pecoraro, R., Simonetta, I., Miceli, S., Arnao, V., Licata, G., & Pinto, A. (2013). Neurological complications of Anderson-Fabry disease. Current Pharmaceutical Design, 19(33), 6014\u20136030.","journal-title":"Current Pharmaceutical Design"},{"issue":"1","key":"440_CR5","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1161\/STROKEAHA.114.006283","volume":"46","author":"E Kolodny","year":"2015","unstructured":"Kolodny, E., Fellgiebel, A., Hilz, M. J., Sims, K., Caruso, P., Phan, T. G., Politei, J., Manara, R., & Burlina, A. (2015). Cerebrovascular involvement in Fabry disease: Current status of knowledge. Stroke, 46(1), 302\u2013313.","journal-title":"Stroke"},{"issue":"6","key":"440_CR6","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s13244-018-0664-8","volume":"9","author":"S Cocozza","year":"2018","unstructured":"Cocozza, S., Russo, C., Pontillo, G., Pisani, A., & Brunetti, A. (2018). Neuroimaging in Fabry disease: Current knowledge and future directions. Insights into Imaging, 9(6), 1077\u20131088.","journal-title":"Insights into Imaging"},{"issue":"6","key":"440_CR7","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.02.019","volume":"25","author":"Y Kono","year":"2016","unstructured":"Kono, Y., Wakabayashi, T., Kobayashi, M., Ohashi, T., Eto, Y., Ida, H., & Iguchi, Y. (2016). Characteristics of cerebral microbleeds in patients with Fabry disease. Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association, 25(6), 1320\u20131325.","journal-title":"Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association"},{"issue":"3","key":"440_CR8","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s00415-020-10209-7","volume":"268","author":"D Lyndon","year":"2021","unstructured":"Lyndon, D., Davagnanam, I., Wilson, D., Jichi, F., Merwick, A., Bolsover, F., Jager, H. R., Cipolotti, L., Wheeler-Kingshott, C., Hughes, D., Murphy, E., Lachmann, R., & Werring, D. J. (2021). MRI-visible perivascular spaces as an imaging biomarker in Fabry disease. Journal of Neurology, 268(3), 872\u2013878.","journal-title":"Journal of Neurology"},{"key":"440_CR9","doi-asserted-by":"publisher","first-page":"100815","DOI":"10.1016\/j.ymgmr.2021.100815","volume":"29","author":"D Tapia","year":"2021","unstructured":"Tapia, D., Floriolli, D., Han, E., Lee, G., Paganini-Hill, A., Wang, S., Zandihaghighi, S., Kimonis, V., & Fisher, M. (2021). Prevalence of cerebral small vessel disease in a Fabry disease cohort. Molecular Genetics and Metabolism Reports, 29, 100815.","journal-title":"Molecular Genetics and Metabolism Reports"},{"key":"440_CR10","doi-asserted-by":"publisher","first-page":"1165324","DOI":"10.3389\/fnagi.2023.1165324","volume":"15","author":"J Botz","year":"2023","unstructured":"Botz, J., Lohner, V., & Schirmer, M. D. (2023). Spatial patterns of white matter hyperintensities: A systematic review. Frontiers in Aging Neuroscience, 15, 1165324.","journal-title":"Frontiers in Aging Neuroscience"},{"key":"440_CR11","doi-asserted-by":"crossref","unstructured":"K\u00f6rver, S., Longo, M. G. F., Lima, M. R., Hollak, C. E. M., Sayed, E., van Schaik, M., Vedolin, I. N., Dijkgraaf, L., M. G. W., & Langeveld, M. (2020). Determinants of cerebral radiological progression in Fabry disease. Journal of neurology, neurosurgery, and psychiatry, 91(7), 756\u2013763.","DOI":"10.1136\/jnnp-2019-322268"},{"issue":"6","key":"440_CR12","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Ermain","year":"2016","unstructured":"Ermain, D. P., Hughes, D. A., Nicholls, K., Bichet, D. G., Giugliani, R., Wilcox, W. R., Feliciani, C., Shankar, S. P., Ezgu, F., Amartino, H., Bratkovic, D., Feldt-Rasmussen, U., Nedd, K., Sharaf El Din, U., Lourenco, C. M., Banikazemi, M., Charrow, J., Dasouki, M., Finegold, D., Giraldo, P., & Schiffmann, R. (2016). Treatment of fabry\u2019s disease with the Pharmacologic chaperone Migalastat. The New England Journal of Medicine, 375(6), 545\u2013555.","journal-title":"The New England Journal of Medicine"},{"key":"440_CR13","doi-asserted-by":"crossref","unstructured":"Lenders, M., Nordbeck, P., Kurschat, C., Karabul, N., Kaufeld, J., Hennermann, J.B., Patten, M., Cybulla, M., M\u00fcntze, J., \u00dc\u00e7eyler, N., Liu, D., Das, A. M., Sommer,C., Pogoda, C., Reiermann, S., Duning, T., Gaedeke, J., Stumpfe, K., Blaschke, D.,Brand, S. M., \u2026 Brand, E. (2020). Treatment of Fabry\u2019s Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS). Clinical pharmacology and therapeutics, 108(2), 326\u2013337.","DOI":"10.1002\/cpt.1832"},{"issue":"3","key":"440_CR14","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/ehjcvp\/pvab025","volume":"8","author":"M Lenders","year":"2022","unstructured":"Lenders, M., Nordbeck, P., Kurschat, C., Eveslage, M., Karabul, N., Kaufeld, J., Hennermann, J., Patten, M., Cybulla, M., M\u00fcntze, J., \u00dc\u00e7eyler, N., Liu, D., Das, A., M, A., Sommer, C., Pogoda, C., Reiermann, S., Duning, T., Gaedeke, J., von Cossel, K., Blaschke, D., & Brand, E. (2022). Treatment of Fabry disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS). European Heart Journal Cardiovascular Pharmacotherapy, 8(3), 272\u2013281.","journal-title":"European Heart Journal Cardiovascular Pharmacotherapy"},{"issue":"6","key":"440_CR15","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40265-021-01486-1","volume":"81","author":"M Lenders","year":"2021","unstructured":"Lenders, M., & Brand, E. (2021). Fabry disease: The current treatment landscape. Drugs, 81(6), 635\u2013645.","journal-title":"Drugs"},{"issue":"5","key":"440_CR16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., Voelkerding, K., Rehm, H. L., & ACMG Laboratory Quality Assurance Committee. (2015). Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genetics in Medicine: Official Journal of the American College of Medical Genetics, 17(5), 405\u2013424.","journal-title":"Genetics in Medicine: Official Journal of the American College of Medical Genetics"},{"issue":"4","key":"440_CR17","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/jimd.12743","volume":"47","author":"A Klein","year":"2024","unstructured":"Klein, A., Klug, K., Breyer, M., Gr\u00fcner, J., Medala, V. K., Nordbeck, P., Wanner, C., Klopocki, E., & \u00dc\u00e7eyler, N. (2024). Genetic variants of unknown significance in alpha-galactosidase A: Cellular delineation from Fabry disease. Journal of Inherited Metabolic Disease, 47(4), 805\u2013817.","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"4","key":"440_CR18","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz, A., Germain, D. P., Desnick, R. J., Politei, J., Mauer, M., Burlina, A., Eng, C., Hopkin, R. J., Laney, D., Linhart, A., Waldek, S., Wallace, E., Weidemann, F., & Wilcox, W. R. (2018). Fabry disease revisited: Management and treatment recommendations for adult patients. Molecular Genetics and Metabolism, 123(4), 416\u2013427.","journal-title":"Molecular Genetics and Metabolism"},{"key":"440_CR19","doi-asserted-by":"crossref","unstructured":"Biegstraaten, M., Arngr\u00edmsson, R., Barbey, F., Boks, L., Cecchi, F., Deegan, P. B.,Feldt-Rasmussen, U., Geberhiwot, T., Germain, D. P., Hendriksz, C., Hughes, D. A.,Kantola, I., Karabul, N., Lavery, C., Linthorst, G. E., Mehta, A., van de Mheen, E.,Oliveira, J. P., Parini, R., Ramaswami, U., \u2026 Hollak, C. E. (2015). Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet journal of rare diseases, 10, 36.","DOI":"10.1186\/s13023-015-0253-6"},{"key":"440_CR20","doi-asserted-by":"crossref","unstructured":"Benjamin, E. R., Della Valle, M. C., Wu, X., Katz, E., Pruthi, F., Bond, S., Bronfin,B., Williams, H., Yu, J., Bichet, D. G., Germain, D. P., Giugliani, R., Hughes, D.,Schiffmann, R., Wilcox, W. R., Desnick, R. J., Kirk, J., Barth, J., Barlow, C., Valenzano,K. J., \u2026 Lockhart, D. J. (2017). The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genetics in medicine: official journal of the American College of Medical Genetics, 19(4), 430\u2013438.","DOI":"10.1038\/gim.2016.122"},{"issue":"4","key":"440_CR21","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","volume":"65","author":"C Whybra","year":"2004","unstructured":"Whybra, C., Kampmann, C., Krummenauer, F., Ries, M., Mengel, E., Miebach, E., Baehner, F., Kim, K., Bajbouj, M., Schwarting, A., Gal, A., & Beck, M. (2004). The Mainz severity score index: A new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clinical Genetics, 65(4), 299\u2013307.","journal-title":"Clinical Genetics"},{"key":"440_CR22","doi-asserted-by":"crossref","unstructured":"Wardlaw, J. M., Smith, E. E., Biessels, G. J., Cordonnier, C., Fazekas, F., Frayne,R., Lindley, R. I., O\u2019Brien, J. T., Barkhof, F., Benavente, O. R., Black, S. E., Brayne,C., Breteler, M., Chabriat, H., Decarli, C., de Leeuw, F. E., Doubal, F., Duering,M., Fox, N. C., Greenberg, S., \u2026 STandards for ReportIng Vascular changes on nEuroimaging(STRIVE v1) (2013). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. The Lancet. Neurology, 12(8), 822\u2013838.","DOI":"10.1016\/S1474-4422(13)70124-8"},{"issue":"2","key":"440_CR23","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2214\/ajr.149.2.351","volume":"149","author":"F Fazekas","year":"1987","unstructured":"Fazekas, F., Chawluk, J. B., Alavi, A., Hurtig, H. I., & Zimmerman, R. A. (1987). MR signal abnormalities at 1.5 T in alzheimer\u2019s dementia and normal aging. AJR American Journal of Roentgenology, 149(2), 351\u2013356.","journal-title":"AJR American Journal of Roentgenology"},{"issue":"1","key":"440_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/0022-510X(93)90041-V","volume":"114","author":"P Scheltens","year":"1993","unstructured":"Scheltens, P., Barkhof, F., Leys, D., Pruvo, J. P., Nauta, J. J., Vermersch, P., Steinling, M., & Valk, J. (1993). A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. Journal of the Neurological Sciences, 114(1), 7\u201312.","journal-title":"Journal of the Neurological Sciences"},{"issue":"2","key":"440_CR25","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1136\/jnnp.2008.153460","volume":"80","author":"FN Doubal","year":"2009","unstructured":"Doubal, F. N., Hokke, P. E., & Wardlaw, J. M. (2009). Retinal microvascular abnormalities and stroke: A systematic review. Journal of Neurology Neurosurgery and Psychiatry, 80(2), 158\u2013165.","journal-title":"Journal of Neurology Neurosurgery and Psychiatry"},{"issue":"12","key":"440_CR26","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","volume":"18","author":"RM Lang","year":"2005","unstructured":"Lang, R. M., Bierig, M., Devereux, R. B., Flachskampf, F. A., Foster, E., Pellikka, P. A., Picard, M. H., Roman, M. J., Seward, J., Shanewise, J. S., Solomon, S. D., Spencer, K. T., Sutton, M. S., Stewart, W. J., Committee, & European Association of Echocardiography. (2005). Recommendations for chamber quantification: A report from the American society of echocardiography\u2019s guidelines and standards committee and the chamber quantification writing Group, developed in conjunction with the European association of Echocardiography, A branch of the European society of cardiology. Journal of the American Society of Echocardiography: Official Publication of the American Society of Echocardiography, 18(12), 1440\u20131463.","journal-title":"Journal of the American Society of Echocardiography: Official Publication of the American Society of Echocardiography"},{"issue":"9","key":"440_CR27","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. L., Castro, A. F. 3rd, Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., Coresh, J., & Chronic Kidney Disease Epidemiology Collaboration. (2009). A new equation to estimate glomerular filtration rate. Annals of Internal Medicine, 150(9), 604\u2013612.","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"440_CR28","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1037\/0033-2909.86.2.420","volume":"86","author":"PE Shrout","year":"1979","unstructured":"Shrout, P. E., & Fleiss, J. L. (1979). Intraclass correlations: Uses in assessing rater reliability. Psychological Bulletin, 86(2), 420\u2013428.","journal-title":"Psychological Bulletin"},{"issue":"1","key":"440_CR29","first-page":"55","volume":"7","author":"WR Smoker","year":"1986","unstructured":"Smoker, W. R., Price, M. J., Keyes, W. D., Corbett, J. J., & Gentry, L. R. (1986). High-resolution computed tomography of the Basilar artery: 1. Normal size and position. AJNR. American Journal of Neuroradiology, 7(1), 55\u201360.","journal-title":"American Journal of Neuroradiology"},{"key":"440_CR30","doi-asserted-by":"crossref","unstructured":"Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi,G., Correale, J., Fazekas, F., Filippi, M., Freedman, M. S., Fujihara, K., Galetta,S. L., Hartung, H. P., Kappos, L., Lublin, F. D., Marrie, R. A., Miller, A. E., Miller,D. H., Montalban, X., Mowry, E. M., \u2026 Cohen, J. A. (2018). Diagnosis of multiple sclerosis:2017 revisions of the McDonald criteria. The Lancet. Neurology, 17(2), 162\u2013173.","DOI":"10.1016\/S1474-4422(17)30470-2"},{"issue":"5","key":"440_CR31","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1111\/ene.15716","volume":"30","author":"J Gronewold","year":"2023","unstructured":"Gronewold, J., Jokisch, M., Schramm, S., Himpfen, H., Ginster, T., Tenhagen, I., Doeppner, T. R., Jockwitz, C., Miller, T., Lehmann, N., Moebus, S., J\u00f6ckel, K. H., Erbel, R., Caspers, S., & Hermann, D. M. (2023). Association of regional white matter hyperintensities with hypertension and cognition in the population-based 1000BRAINS study. European Journal of Neurology, 30(5), 1174\u20131190. Heinz Nixdorf Recall Study Investigative Group.","journal-title":"European Journal of Neurology"},{"issue":"2","key":"440_CR32","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1177\/0271678X16635657","volume":"37","author":"S Mu\u00f1oz Maniega","year":"2017","unstructured":"Mu\u00f1oz Maniega, S., Chappell, F. M., Vald\u00e9s Hern\u00e1ndez, M. C., Armitage, P. A., Makin, S. D., Heye, A. K., Thrippleton, M. J., Sakka, E., Shuler, K., Dennis, M. S., & Wardlaw, J. M. (2017). Integrity of normal-appearing white matter: Influence of age, visible lesion burden and hypertension in patients with small-vessel disease. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism, 37(2), 644\u2013656.","journal-title":"Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism"},{"issue":"15","key":"440_CR33","doi-asserted-by":"publisher","first-page":"e1413","DOI":"10.1212\/WNL.0000000000006316","volume":"91","author":"JD Stefaniak","year":"2018","unstructured":"Stefaniak, J. D., Parkes, L. M., Parry-Jones, A. R., Potter, G. M., Vail, A., Jovanovic, A., & Smith, C. J. (2018). Enzyme replacement therapy and white matter hyperintensity progression in Fabry disease. Neurology, 91(15), e1413\u2013e1422.","journal-title":"Neurology"},{"issue":"6","key":"440_CR34","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1159\/000369293","volume":"38","author":"A Fellgiebel","year":"2014","unstructured":"Fellgiebel, A., Gartenschl\u00e4ger, M., Wildberger, K., Scheurich, A., Desnick, R. J., & Sims, K. (2014). Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease. Cerebrovascular Diseases (Basel Switzerland), 38(6), 448\u2013456.","journal-title":"Cerebrovascular Diseases (Basel Switzerland)"},{"issue":"7","key":"440_CR35","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/ejhf.1960","volume":"22","author":"A Linhart","year":"2020","unstructured":"Linhart, A., Germain, D. P., Olivotto, I., Akhtar, M. M., Anastasakis, A., Hughes, D., Namdar, M., Pieroni, M., Hag\u00e8ge, A., Cecchi, F., Gimeno, J. R., Limongelli, G., & Elliott, P. (2020). An expert consensus document on the management of cardiovascular manifestations of Fabry disease. European Journal of Heart Failure, 22(7), 1076\u20131096.","journal-title":"European Journal of Heart Failure"},{"issue":"1","key":"440_CR36","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13023-023-02759-6","volume":"18","author":"YLT Lam","year":"2023","unstructured":"Lam, Y. L. T., Sheng, B., Kwok, H. M., Yu, E. L. M., & Ma, K. F. J. (2023). Basilar artery diameter as neuroimaging biomarker in Chinese Fabry disease patients. Orphanet Journal of Rare Diseases, 18(1), 186.","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"4","key":"440_CR37","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1161\/STROKEAHA.118.024426","volume":"50","author":"K Miwa","year":"2019","unstructured":"Miwa, K., Yagita, Y., Sakaguchi, M., Kitagawa, K., Sakai, N., & Mochizuki, H. (2019). Effect of enzyme replacement therapy on Basilar artery diameter in male patients with Fabry disease. Stroke, 50(4), 1010\u20131012.","journal-title":"Stroke"},{"key":"440_CR38","doi-asserted-by":"crossref","unstructured":"Zheng, T., Tang, W., Shan, Y., Guo, R., Gao, Y., Tian, C., Liu, L., Sun, L., Liu, W., Zhou, Z., Jin, Y., Duan, S., Han, B., Fan, Y., Zhu, X., & Liu, Z. (2023). Studying the imaging features and infarction mechanism of vertebrobasilar Dolichoectasia with high-resolution magnetic resonance imaging. Brain Pathology (Zurich Switzerland), 33(2), e13135.","DOI":"10.1111\/bpa.13135"},{"key":"440_CR39","doi-asserted-by":"crossref","unstructured":"B\u00f6ttcher, T., Rolfs, A., Tanislav, C., Bitsch, A., K\u00f6hler, W., Gaedeke, J., Giese, A. K., Kolodny, E. H., & Duning, T. (2013). Fabry disease - underestimated in the differential diagnosis of multiple sclerosis? PloS One, 8(8), e71894.","DOI":"10.1371\/journal.pone.0071894"},{"issue":"Pt 11","key":"440_CR40","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1093\/brain\/120.11.2059","volume":"120","author":"F Barkhof","year":"1997","unstructured":"Barkhof, F., Filippi, M., Miller, D. H., Scheltens, P., Campi, A., Polman, C. H., Comi, G., Ad\u00e8r, H. J., Losseff, N., & Valk, J. (1997). Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain: a Journal of Neurology, 120(Pt 11), 2059\u20132069.","journal-title":"Brain: a Journal of Neurology"},{"key":"440_CR41","doi-asserted-by":"publisher","first-page":"104936","DOI":"10.1016\/j.msard.2023.104936","volume":"78","author":"NG DuBose","year":"2023","unstructured":"DuBose, N. G., DeJonge, S. R., Jeng, B., & Motl, R. W. (2023). Vascular dysfunction in multiple sclerosis: Scoping review of current evidence for informing future research directions. Multiple Sclerosis and Related Disorders, 78, 104936.","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"1","key":"440_CR42","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12933-016-0483-5","volume":"16","author":"A Tuttolomondo","year":"2017","unstructured":"Tuttolomondo, A., Casuccio, A., Guercio, G., Maida, C., Del Cuore, A., Di Raimondo, D., Simonetta, I., Di Bona, D., Pecoraro, R., Della Corte, V., Gulotta, E., Gulotta, G., & Pinto, A. (2017). Arterial stiffness, endothelial and cognitive function in subjects with type 2 diabetes in accordance with absence or presence of diabetic foot syndrome. Cardiovascular Diabetology, 16(1), 2.","journal-title":"Cardiovascular Diabetology"},{"key":"440_CR43","doi-asserted-by":"crossref","unstructured":"Ugga, L., Cocozza, S., Pontillo, G., Russo, C., Morra, B., Lanzillo, V., Riccio, R., Pisani, E., A., & Brunetti, A. (2018). Absence of infratentorial lesions in Fabry disease contributes to differential diagnosis with multiple sclerosis. Brain and Behavior, 8(11), e01121.","DOI":"10.1002\/brb3.1121"},{"key":"440_CR44","doi-asserted-by":"crossref","unstructured":"Sati, P., Oh, J., Constable, R. T., Evangelou, N., Guttmann, C. R., Henry, R. G.,Klawiter, E. C., Mainero, C., Massacesi, L., McFarland, H., Nelson, F., Ontaneda,D., Rauscher, A., Rooney, W. D., Samaraweera, A. P., Shinohara, R. T., Sobel, R. A.,Solomon, A. J., Treaba, C. A., Wuerfel, J., \u2026 NAIMS Cooperative (2016). The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nature reviews. Neurology, 12(12), 714\u2013722.","DOI":"10.1038\/nrneurol.2016.166"},{"issue":"6","key":"440_CR45","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1007\/s00330-021-08487-4","volume":"32","author":"M Tranfa","year":"2022","unstructured":"Tranfa, M., Tortora, M., Pontillo, G., Iuzzolino, V., Riccio, E., Caccavallo, S., Di Risi, T., Monti, S., Lanzillo, R., Morra, B., Palma, V., Petracca, G., Pisani, M., Brunetti, A., A., & Cocozza, S. (2022). The central vein sign helps in differentiating multiple sclerosis from its mimickers: Lessons from Fabry disease. European Radiology, 32(6), 3846\u20133854.","journal-title":"European Radiology"}],"container-title":["Neurological Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-025-00440-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42466-025-00440-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42466-025-00440-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:02:58Z","timestamp":1765929778000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42466-025-00440-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["440"],"URL":"https:\/\/doi.org\/10.1186\/s42466-025-00440-w","relation":{},"ISSN":["2524-3489"],"issn-type":[{"value":"2524-3489","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All investigations were performed according to the Declaration of Helsinki. All investigations were performed after approval by the respective ethics committees of the participating centers (project number: 2016-401-f-S,\n                      \n                      ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ML received speaker honoraria, travel funding, and research grants from Amicus Therapeutics, Sanofi, Chiesi, and Takeda. SCK received speaker honoraria, travel funding from Amicus Therapeutics, Sanofi, Chiesi, and Takeda. CK received speaker honoraria and travel support from Amicus Therapeutics, Chiesi, Sanofi, and Takeda. NM is a consultant for and\/or received speak-er\u2019s honoraria and travel grants from Amicus Therapeutics, Biomarin, Chiesi, JCR, Sanofi, Takeda, and Orphazyme. JBH received consulting fees and\/or honoraria from Chiesi, Sanofi, Takeda, Amicus, and Immedica and travel support from Chiesi and Amicus. MCy received speaker honoraria\/travel grants from Takeda, Amicus Therapeutics, Idorsia, and Alexion. JK received speaker honoraria and\/or travel funding from Amicus Therapeutics, Sanofi, Chiesi, Novartis, Takeda, and Alexion (Astrazeneca Rare Disease). EB received research grants and speaker honoraria from Sanofi, Takeda, Chiesi and Amicus Therapeutics. AB received speaker honoraria from Amicus Therapeutics and Biogen. MC, PL, and MM report no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"98"}}